The assessment of ERα, PgR and HER2 status is routinely performed today to determine the endocrine responsiveness of breast cancer samples. Such determination is usually accomplished by means of immunohistochemistry and in case of HER2 amplification by means of fluorescent in situ hybridization (FISH). The analysis of these markers can be improved by simultaneous measurements using quantitative real-time PCR (Qrt-PCR). In this study we compared Qrt-PCR results for the assessment of mRNA levels of ERα, PgR, and the members of the human epidermal growth factor receptor family, HER1, HER2, HER3 and HER4. The results were obtained in two independent laboratories using two different methods, SYBR Green I and TaqMan probes, and different primers. By linear regression we demonstrated a good concordance for all six markers. The quantitative mRNA expression levels of ERα, PgR and HER2 also strongly correlated with the respective quantitative protein expression levels prospectively detected by EIA in both laboratories. In addition, HER2 mRNA expression levels correlated well with gene amplification detected by FISH in the same biopsies. Our results indicate that both Qrt-PCR methods were robust and sensitive tools for routine diagnostics and consistent with standard methodologies. The developed simultaneous assessment of several biomarkers is fast and labor effective and allows optimization of the clinical decision-making process in breast cancer tissue and/or core biopsies.
GoldhirschA., WoodW.C., GelberR.D.Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer. J Clin Oncol2003; 21: 3357–65.
2.
GoldhirschA., GlickJ.H., GelberR.D.Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol2005; 16: 1569–83.
3.
OsborneC.K., BardouV., HoppT.A.Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst2003; 95: 353–61.
4.
KonecnyG., PaulettiG., PegramM.Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer. J Natl Cancer Inst2003; 95: 142–53.
5.
TaucherS., RudasM., MaderR.M.Do we need HER-2/neu testing for all patients with primary breast carcinoma?Cancer2003; 98: 2547–53.
6.
SchiffR., MassarwehS.A., ShouJ.Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance. Clin Cancer Res2004; 10: 331S–6S.
7.
PaikS., BryantJ., Tan-ChiuE.HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15. J Natl Cancer Inst2000; 92: 1991–8.
8.
FurukawaY., KimijimaI.I., AbeR.Immunohistochemical image analysis of estrogen and progesterone receptors in breast cancer. Breast Cancer1998; 5: 375–80.
9.
SunC.F., WuT.L., TsaoK.C.Development of two ELISA for estrogen and progesterone receptor with sufficient sensitivity for fine needle aspirate and core biopsy. J Clin Lab Anal2001; 15: 138–43.
10.
BilousM., AdesC., ArmesJ.Predicting the HER2 status of breast cancer from basic histopathology data: an analysis of 1500 breast cancers as part of the HER2000 International Study. Breast2003; 12: 92–8.
11.
Eppenberger-CastoriS., KuengW., BenzC.Prognostic and predictive significance of ErbB-2 breast tumor levels measured by enzyme immunoassay. J Clin Oncol2001; 19: 645–56.
12.
HammockL., LewisM., PhillipsC.Strong HER-2/neu protein overexpression by immunohistochemistry often does not predict oncogene amplification by fluorescence in situ hybridization. Hum Pathol2003; 34: 1043–7.
13.
PersonsD.L., BuiM.M., LoweryM.C.Fluorescence in situ hybridization (FISH) for detection of HER-2/neu amplification in breast cancer: a multicenter portability study. Ann Clin Lab Sci2000; 30: 41–8.
14.
PerezE.A., RocheP.C., JenkinsR.B.HER2 testing in patients with breast cancer: poor correlation between weak positivity by immunohistochemistry and gene amplification by fluorescence in situ hybridization. Mayo Clin Proc2002; 77: 148–54.
15.
de CremouxP., Tran-PerennouC., ElieC.Quantitation of estradiol receptors alpha and beta and progesterone receptors in human breast tumors by real-time reverse transcription-polymerase chain reaction. Correlation with protein assays. Biochem Pharmacol2002; 64: 507–15.
16.
IwaoK., MiyoshiY., EgawaC.Quantitative analysis of estrogen receptor-alpha and -beta messenger RNA expression in breast carcinoma by real-time polymerase chain reaction. Cancer2000; 89: 1732–8.
17.
BecetteV., VignaudS., RegnierC.Gene transcript assay by real-time RT-PCR in epithelial breast cancer cells selected by laser microdissection. Int J Biol Markers2004; 19: 100–8.
18.
HudelistG., SingerC.F., ManaviM.Co-expression of ErbB-family members in human breast cancer: Her-2/neu is the preferred dimerization candidate in nodal-positive tumors. Breast Cancer Res Treat2003; 80: 353–61.
19.
SuoZ., RisbergB., KalssonM.G.EGFR family expression in breast carcinomas. c-erbB-2 and c-erbB-4 receptors have different effects on survival. J Pathol2002; 196: 17–25.
20.
EppenbergerU., KuengW., SchlaeppiJ.M.Markers of tumor angiogenesis and proteolysis independently define high- and low-risk subsets of node-negative breast cancer patients. J Clin Oncol1998; 16: 3129–3136.
21.
SchmittM., HarbeckN., DaidoneM.G.Identification, validation, and clinical implementation of tumor-associated biomarkers to improve therapy concepts, survival, and quality of life of cancer patients: tasks of the Receptor and Biomarker Group of the European Organization for Research and Treatment of Cancer. Int J Oncol2004; 25: 1397–406.
22.
SauerT., WiedswangG., BoudjemaG.Assessment of HER-2/neu overexpression and/or gene amplification in breast carcinomas: should in situ hybridization be the method of choice?Apmis2003; 111: 444–50.
23.
RocchiP., MuraccioleX., FinaF.Molecular analysis integrating different pathways associated with androgen-independent progression in LuCaP 23.1 xenograft. Oncogene2004; 23: 9111–9.
24.
PassingH., BablokW.A new biometrical procedure for testing the equality of measurements from two different analytical methods. Application of linear regression procedures for method comparison studies in clinical chemistry, Part I. J Clin Chem Clin Biochem1983; 21: 709–20.
25.
WestgardJ.O.Points of care in using statistics in method comparison studies. Clin Chem1998; 44: 2240–2.
26.
de CremouxP., BiecheI., Tran-PerennouC.Inter-laboratory quality control for hormone-dependent gene expression in human breast tumors using real-time reverse transcription-polymerase chain reaction. Endocr Relat Cancer2004; 11: 489–95.
27.
WhiteS.L., GharbiS., BertaniM.F.Cellular responses to ErbB-2 overexpression in human mammary luminal epithelial cells: comparison of mRNA and protein expression. Br J Cancer2004; 90: 173–81.
28.
BrownP.O., BotsteinD.Exploring the new world of the genome with DNA microarrays. Nat Genet1999; 21: 33–7.
29.
BlameyR.W.Guidelines on endocrine therapy of breast cancer EUSOMA. Eur J Cancer2002; 38: 615–34.
30.
QuerzoliP., MarchettiE., FabrisG.Immunohistochemical expression of c-erbB-2 in human breast cancer by monoclonal antibody: correlation with lymph node and ER status. Tumori1990; 76: 461–4.
31.
YehI.T.Measuring HER-2 in breast cancer. Immunohistochemistry, FISH, or ELISA? Am J Clin Pathol2002; 117(Suppl): S26–35.
32.
SauterG., FeichterG., TorhorstJ.Fluorescence in situ hybridization for detecting erbB-2 amplification in breast tumor fine needle aspiration biopsies. Acta Cytol1996; 40: 164–73.
33.
SimonM., KosterG., LudwigM.Alternative splicing of the p15 cdk inhibitor in glioblastoma multiforme. Acta Neuropathol (Berl)2001; 102: 167–74.
34.
Merkelbach-BruseS., WardelmannE., BehrensP.Current diagnostic methods of HER-2/neu detection in breast cancer with special regard to real-time PCR. Am J Surg Pathol2003; 27: 1565–70.
35.
GinestierC., Charafe-JauffretE., Penault-LlorcaF.Comparative multi-methodological measurement of ERBB2 status in breast cancer. J Pathol2004; 202: 286–98.
36.
BustinS.A.Quantification of mRNA using real-time reverse transcription PCR (RT-PCR): trends and problems. J Mol Endocrinol2002; 29: 23–39.
37.
KnowldenJ.M., GeeJ.M., SeeryL.T.c-erbB3 and c-erbB4 expression is a feature of the endocrine responsive phenotype in clinical breast cancer. Oncogene1998; 17: 1949–57.
38.
HolbroT., BeerliR.R., MaurerF.The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proc Natl Acad Sci U S A2003; 100: 8933–8.
39.
ByersR., RoebuckJ., SakhiniaE.PolyA PCR amplification of cDNA from RNA extracted from formalin-fixed paraffin-embedded tissue. Diagn Mol Pathol2004; 13: 144–50.
40.
PaikS., ShakS., TangG.A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med2004; 351: 2817–26.
41.
AntonovJ., GoldsteinD.R., OberliA.Reliable gene expression measurements from degraded RNA by quantitative real-time PCR depend on short amplicons and a proper normalization. Lab Invest2005; 85: 1040–50.
42.
VincekV., NassiriM., BlockN.Methodology for preservation of high molecular-weight RNA in paraffin-embedded tissue: application for laser-capture microdissection. Diagn Mol Pathol2005; 14: 127–33.
